查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1511905

美国更年期市场规模、份额和趋势分析报告：按治疗方法和细分市场预测，2024-2030 年

U.S. Menopause Market Size, Share & Trends Analysis Report By Treatment (Dietary Supplements, OTC Pharma Products), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国更年期市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，美国更年期市场规模预计将达到73亿美元，预测期内复合年增长率为4.8%。

世界上越来越多的老年女性进入更年期并出现相关症状，导致对更年期相关产品、服务和治疗的需求增加。此外，由于人们越来越偏好天然和有机更年期疾病治疗药物，美国的更年期疾病市场正在扩大。此外，先进产品和技术的引入，例如无激素治疗方法和远端医疗服务，也支持了市场成长。

吸烟、饮酒和肥胖等生活习惯会使更年期症状恶化，导致更年期治疗的需求增加。生活方式不健康的女性可能会出现更严重的更年期症状，预计将推动市场成长。美国国家医学图书馆发表的一项研究发现，肥胖吸烟者出现更频繁和更严重血管舒缩症状的风险显着增加。

个人化医疗根据每位患者的需求提供量身定制的治疗，正受到越来越多的关注。例如，2023 年 3 月，密西根州 Blue Cross Blue Shield 和 Blue Care Network 宣布推出女性健康解决方案，以帮助会员度过更年期。家庭建设和妇女健康支持解决方案的一个关键功能是提供个人化护理的数位应用程序，使成员能够识别症状、探索治疗方案、与专家联繫并参与同伴社区的帮助支持。

美国更年期市场报告亮点

  • 由于更年期自然治疗方法和成分的认知度、可用性和价格不断提高，营养食品将在治疗领域占据主导地位，到 2023 年将占据约 95% 的销售份额。
  • 对副作用和长期健康风险的担忧导致女性转向更年期非荷尔蒙治疗，例如草药补充品、针灸和认知行为疗法。
  • 2024 年 1 月，Dr. Reddy's Laboratories Ltd. 从 Amyris, Inc. 收购了 MenoLabs，这是一个针对女性健康的营养食品组合。 美国 Reddy’s 现在拥有全部七种 MenoLabs补充品，包括 MenoGlow、MenoFit 和 Happy Fiber 等益生菌，旨在改善更年期和更年期症状。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章美国更年期市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国更年期市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国更年期市场：治疗评估与趋势分析

  • 2023 年及 2030 年泡沫市场占有率
  • 细分仪表板
  • 美国更年期市场前景：依治疗方法分类
  • 2018-2030年市场规模、预测及趋势分析

第五章竞争状况

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
  • 公司简介
    • Pfizer Inc.
    • Novo Nordisk A/S
    • TherapeuticsMD
    • Bayer AG
    • AbbVie, Inc.
    • Pure Encapsulations, LLC.
    • PADAGIS LLC
Product Code: GVR-4-68040-310-1

U.S. Menopause Market Growth & Trends:

The U.S. menopause market size is anticipated to reach USD 7.3 billion by 2030, growing at a CAGR of 4.8% during the forecast period, according to a new report by Grand View Research, Inc. The rising aging women population worldwide reaching menopause and its related symptoms are resulting in a growing demand for menopause-related products, services, and treatments. In addition, the menopause market in the U.S. is expanding due to the rising inclination towards natural and organic menopause remedies. Furthermore, the market growth is also supported by the introduction of advanced products and technologies, such as hormone-free therapies and telemedicine services.

Lifestyle factors such as smoking, alcohol consumption, and obesity can exacerbate menopause symptoms, leading to an increased demand for menopause treatments. Women who lead unhealthy lifestyles are more likely to experience severe menopause symptoms, which is expected to drive the market's growth. According to a study published by the National Library of Medicine, the risk of frequent or severe vasomotor symptoms increased significantly among obese smokers.

There has been a growing focus on personalized medicine, with treatments tailored to each patient's individual needs However, several smaller companies specialize in niche areas of the market, such as alternative therapies or personalized medicine approaches. For instance, in March 2023, Blue Cross Blue Shield of Michigan and Blue Care Network introduced a women's health solution to aid their members in transitioning into menopause. A key feature of the Family Building and Women's Health Support Solution is a digital app that provides personalized care, helping members identify symptoms, explore treatment options, connect with experts, and join peer communities for support.

U.S. Menopause Market Report Highlights:

  • Dietary supplements dominated the treatment segment with around 95% of the revenue share in 2023, owing to the increasing awareness, availability, and affordability of natural treatments and ingredients during the menopause stage
  • Women are opting for non-hormonal treatments for menopause, such as herbal supplements, acupuncture, and cognitive-behavioral therapy, due to concerns about side effects and long-term health risks
  • In January 2024, Dr. Reddy's Laboratories Ltd. acquired MenoLabs, a portfolio of dietary supplements for women's health, from Amyris, Inc. The U.S. Dr. Reddy's now owns all seven MenoLabs supplements, which are designed to help with symptoms of perimenopause and menopause, including probiotics like MenoGlow, MenoFit, and Happy Fiber.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Menopause Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Menopause Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Menopause Market: Treatment Estimates & Trend Analysis

  • 4.1. Form Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Menopause Market by Treatment Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Dietary Supplements
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. OTC Pharma Products
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Hormonal
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Non Hormonal
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Competitive Landscape

  • 5.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 5.2. Company/Competition Categorization
  • 5.3. Vendor Landscape
    • 5.3.1. List of key distributors and channel partners
    • 5.3.2. Key customers
    • 5.3.3. Key company heat map analysis, 2023
  • 5.4. Company Profiles
    • 5.4.1. Pfizer Inc.
      • 5.4.1.1. Company overview
      • 5.4.1.2. Financial performance
      • 5.4.1.3. Product benchmarking
      • 5.4.1.4. Strategic initiatives
    • 5.4.2. Novo Nordisk A/S
      • 5.4.2.1. Company overview
      • 5.4.2.2. Financial performance
      • 5.4.2.3. Product benchmarking
      • 5.4.2.4. Strategic initiatives
    • 5.4.3. TherapeuticsMD
      • 5.4.3.1. Company overview
      • 5.4.3.2. Financial performance
      • 5.4.3.3. Product benchmarking
      • 5.4.3.4. Strategic initiatives
    • 5.4.4. Bayer AG
      • 5.4.4.1. Company overview
      • 5.4.4.2. Financial performance
      • 5.4.4.3. Product benchmarking
      • 5.4.4.4. Strategic initiatives
    • 5.4.5. AbbVie, Inc.
      • 5.4.5.1. Company overview
      • 5.4.5.2. Financial performance
      • 5.4.5.3. Product benchmarking
      • 5.4.5.4. Strategic initiatives
    • 5.4.6. Pure Encapsulations, LLC.
      • 5.4.6.1. Company overview
      • 5.4.6.2. Financial performance
      • 5.4.6.3. Product benchmarking
      • 5.4.6.4. Strategic initiatives
    • 5.4.7. PADAGIS LLC
      • 5.4.7.1. Company overview
      • 5.4.7.2. Financial performance
      • 5.4.7.3. Product benchmarking
      • 5.4.7.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. Menopause market, by treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. menopause market: market outlook
  • Fig. 9 U.S. menopause competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. menopause market driver impact
  • Fig. 14 U.S. menopause market restraint impact
  • Fig. 15 U.S. menopause market: Treatment movement analysis
  • Fig. 16 U.S. menopause market: Treatment outlook and key takeaways
  • Fig. 17 Dietary supplements market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 OTC pharma products estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Hormonal estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Non hormonal market estimates and forecasts, 2018 - 2030 (USD Million)